These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1072 related articles for article (PubMed ID: 16364513)

  • 1. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV; Turbyfill KR
    Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a.
    Turbyfill KR; Kaminski RW; Oaks EV
    Vaccine; 2008 Mar; 26(10):1353-64. PubMed ID: 18276045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of
    Turbyfill KR; Clarkson KA; Vortherms AR; Oaks EV; Kaminski RW
    mSphere; 2018; 3(2):. PubMed ID: 29600284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers.
    Tribble D; Kaminski R; Cantrell J; Nelson M; Porter C; Baqar S; Williams C; Arora R; Saunders J; Ananthakrishnan M; Sanders J; Zaucha G; Turbyfill R; Oaks E
    Vaccine; 2010 Aug; 28(37):6076-85. PubMed ID: 20619378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.
    Riddle MS; Kaminski RW; Williams C; Porter C; Baqar S; Kordis A; Gilliland T; Lapa J; Coughlin M; Soltis C; Jones E; Saunders J; Keiser PB; Ranallo RT; Gormley R; Nelson M; Turbyfill KR; Tribble D; Oaks EV
    Vaccine; 2011 Sep; 29(40):7009-19. PubMed ID: 21787825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
    Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.
    Kaminski RW; Wu M; Turbyfill KR; Clarkson K; Tai B; Bourgeois AL; Van De Verg LL; Walker RI; Oaks EV
    Clin Vaccine Immunol; 2014 Mar; 21(3):366-82. PubMed ID: 24403527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine.
    Turbyfill KR; Hartman AB; Oaks EV
    Infect Immun; 2000 Dec; 68(12):6624-32. PubMed ID: 11083774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.
    McKenzie R; Walker RI; Nabors GS; Van De Verg LL; Carpenter C; Gomes G; Forbes E; Tian JH; Yang HH; Pace JL; Jackson WJ; Bourgeois AL
    Vaccine; 2006 May; 24(18):3735-45. PubMed ID: 16095766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.
    Jennison AV; Roberts F; Verma NK
    FEMS Immunol Med Microbiol; 2006 Apr; 46(3):444-51. PubMed ID: 16553820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine potential for inactivated shigellae.
    Osorio M; Bray MD; Walker RI
    Vaccine; 2007 Feb; 25(9):1581-92. PubMed ID: 17178431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
    Shim DH; Chang SY; Park SM; Jang H; Carbis R; Czerkinsky C; Uematsu S; Akira S; Kweon MN
    Vaccine; 2007 Jun; 25(25):4828-36. PubMed ID: 17507120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a stable and non-resistant bivalent vaccine candidate strain against Shigella flexneri 2a and Shigella sonnei.
    Rui X; Xu Y; Wan H; Su G; Huang C
    Chin J Biotechnol; 1996; 12(2):89-97. PubMed ID: 8988355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shigellosis: the current status of vaccine development.
    Kweon MN
    Curr Opin Infect Dis; 2008 Jun; 21(3):313-8. PubMed ID: 18448978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production.
    Lin J; Smith MA; Benjamin WH; Kaminski RW; Wenzel H; Nahm MH
    Clin Vaccine Immunol; 2016 Aug; 23(8):681-8. PubMed ID: 27280622
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Clarkson KA; Porter CK; Talaat KR; Frenck RW; Alaimo C; Martin P; Bourgeois AL; Kaminski RW
    mSphere; 2021 Aug; 6(4):e0012221. PubMed ID: 34259559
    [No Abstract]   [Full Text] [Related]  

  • 17. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
    Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral administration of live Shigella vaccine candidates in rhesus monkeys show no evidence of competition for colonization and immunogenicity between different serotypes.
    Ranallo RT; Kaminski R; Baqar S; Dutta M; Lugo-Roman LA; Boren T; Barnoy S; Venkatesan MM
    Vaccine; 2014 Mar; 32(15):1754-60. PubMed ID: 24522159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of the
    Turbyfill KR; Clarkson KA; Oaks EV; Zurawski DV; Vortherms AR; Kaminski RW
    mSphere; 2023 Aug; 8(4):e0007323. PubMed ID: 37389412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Shigella flexneri 2a and Shigella sonnei I live vaccinal strains. Characterization of immunogenicity in animal models.
    Denchev V; Sumerska T; Marinova S; Vassilev T; Panova I; Linde K
    Acta Microbiol Hung; 1990; 37(4):359-66. PubMed ID: 2099082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.